Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation

HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) and umbilical cord blood transplantation (UCBT) are alternative to HLA-matched stem cell transplantation. We conducted a matched-pair analysis of PTCy-haplo and UCBT using the Japanese registry data. We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone marrow transplantation (Basingstoke) 2022-11, Vol.57 (11), p.1681-1688
Hauptverfasser: Sugita, Junichi, Atsuta, Yoshiko, Nakamae, Hirohisa, Maruyama, Yumiko, Ishiyama, Ken, Shiratori, Souichi, Fukuda, Takahiro, Kurata, Mio, Shingai, Naoki, Ozawa, Yukiyasu, Masuko, Masayoshi, Nagafuji, Koji, Uchida, Naoyuki, Tanaka, Masatsugu, Onizuka, Makoto, Kanda, Junya, Kimura, Takafumi, Ichinohe, Tatsuo, Teshima, Takanori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) and umbilical cord blood transplantation (UCBT) are alternative to HLA-matched stem cell transplantation. We conducted a matched-pair analysis of PTCy-haplo and UCBT using the Japanese registry data. We identified 136 patients aged between 16 and 69 years who received PTCy-haplo as their first transplantation for acute leukemia or myelodysplastic syndromes. Control group included 408 UCBT recipients selected to match the PTCy-haplo group. Overall and relapse-free survival probabilities at 2 years were comparable between the PTCy-haplo and UCBT groups: 55% vs. 53% for overall survival ( p  = 0.46), and 47% vs. 48% for relapse-free survival ( p  = 0.79), respectively. The cumulative incidence of relapse was significantly higher (43% vs. 29%, respectively, p  = 0.006), while the cumulative incidence of non-relapse mortality (NRM) was significantly lower (9% vs. 23%, respectively, p  
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-022-01770-y